MA38390A1 - Composés tétrahydropyrrolothiazines - Google Patents

Composés tétrahydropyrrolothiazines

Info

Publication number
MA38390A1
MA38390A1 MA38390A MA38390A MA38390A1 MA 38390 A1 MA38390 A1 MA 38390A1 MA 38390 A MA38390 A MA 38390A MA 38390 A MA38390 A MA 38390A MA 38390 A1 MA38390 A1 MA 38390A1
Authority
MA
Morocco
Prior art keywords
tetrahydropyrrolothiazine
compounds
tetrahydropyrrolothiazine compounds
compound
formula
Prior art date
Application number
MA38390A
Other languages
English (en)
Other versions
MA38390B1 (fr
Inventor
Steven James Green
Dustin James Mergott
Brian Morgan Watson
Jr Leonard Larry Winneroski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA38390A1 publication Critical patent/MA38390A1/fr
Publication of MA38390B1 publication Critical patent/MA38390B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne un composé de formule (i), dans laquelle r est h ou f ; et a est : (a), (b), (c) ou (d) ; ou un sel pharmaceutiquement acceptable de celui-ci.
MA38390A 2013-03-12 2014-03-04 Composés tétrahydropyrrolothiazines MA38390B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776819P 2013-03-12 2013-03-12
PCT/US2014/020070 WO2014143579A1 (fr) 2013-03-12 2014-03-04 Composés tétrahydropyrrolothiazines

Publications (2)

Publication Number Publication Date
MA38390A1 true MA38390A1 (fr) 2018-08-31
MA38390B1 MA38390B1 (fr) 2020-01-31

Family

ID=50382615

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38390A MA38390B1 (fr) 2013-03-12 2014-03-04 Composés tétrahydropyrrolothiazines

Country Status (37)

Country Link
US (3) US8841293B1 (fr)
EP (1) EP2970336B1 (fr)
JP (1) JP6095844B2 (fr)
KR (1) KR101688761B1 (fr)
CN (1) CN105026404B (fr)
AP (1) AP2015008713A0 (fr)
AR (1) AR094918A1 (fr)
BR (1) BR112015018738A8 (fr)
CA (1) CA2898500C (fr)
CL (1) CL2015002529A1 (fr)
CR (1) CR20150418A (fr)
CY (1) CY1119585T1 (fr)
DK (1) DK2970336T3 (fr)
EA (1) EA026006B1 (fr)
ES (1) ES2653421T3 (fr)
HR (1) HRP20171851T1 (fr)
HU (1) HUE037487T2 (fr)
IL (1) IL240903B (fr)
JO (1) JO3317B1 (fr)
LT (1) LT2970336T (fr)
MA (1) MA38390B1 (fr)
ME (1) ME02910B (fr)
MX (1) MX2015012628A (fr)
MY (1) MY180083A (fr)
NO (1) NO3039297T3 (fr)
NZ (1) NZ712207A (fr)
PE (1) PE20151542A1 (fr)
PH (1) PH12015502031B1 (fr)
PL (1) PL2970336T3 (fr)
PT (1) PT2970336T (fr)
RS (1) RS56645B1 (fr)
SG (1) SG11201507499XA (fr)
SI (1) SI2970336T1 (fr)
TN (1) TN2015000340A1 (fr)
TW (1) TWI593692B (fr)
UA (1) UA112941C2 (fr)
WO (1) WO2014143579A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN09346A (fr) 2012-06-13 2015-07-17 Hoffmann La Roche
KR102179599B1 (ko) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 이환형 유도체
PL2912041T3 (pl) 2012-10-26 2017-06-30 Eli Lilly And Company Pochodne tetrahydropirolotiazyny stanowiące inhibitory BACE
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
CN105764905B (zh) 2013-11-26 2019-06-07 豪夫迈·罗氏有限公司 新的八氢-环丁二烯并[1，2-c；3，4-c’]二吡咯-2基
TWI684452B (zh) 2014-03-14 2020-02-11 美國禮來大藥廠 胺基噻嗪化合物
WO2015144609A1 (fr) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Composés condensés de [1,4]diazépine en tant qu'inhibiteurs d'autotaxine (atx) et de production d'acide lysophosphatidique (lpa)
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
TWI570127B (zh) * 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
AR103406A1 (es) * 2015-01-30 2017-05-10 Lilly Co Eli Sal de tosilato
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
CA2992889A1 (fr) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Derives de phenoxymethyle
KR20180054830A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서의 이환형 화합물
RU2018112230A (ru) 2015-09-24 2019-10-30 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов atx
CR20180057A (es) 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
AR107774A1 (es) * 2016-03-16 2018-05-30 Lilly Co Eli Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
WO2018112084A1 (fr) 2016-12-15 2018-06-21 Amgen Inc. Dérivés de thiazine et d'oxazine bicycliques en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
JP7149271B2 (ja) 2016-12-15 2022-10-06 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としての１，４－チアジンジオキシドおよび１，２，４－チアジアジンジオキシド誘導体ならびに使用方法
US10947223B2 (en) 2016-12-15 2021-03-16 Amgen Inc. Substituted oxazines as beta-secretase inhibitors
JP7149272B2 (ja) 2016-12-15 2022-10-06 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としてのチアジン誘導体および使用方法
EP3555085B1 (fr) 2016-12-15 2020-12-02 Amgen Inc. Derivés thiazine fusionnés à un cyclopropyle utilisés en tant qu'inhibiteurs de la bêta-sécrétase et procédés d'utilisation
WO2018167113A1 (fr) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag Nouveaux composés bicycliques utilisés en tant qu'inhibiteurs d'atx
SG11201908560SA (en) 2017-03-16 2019-10-30 Hoffmann La Roche Heterocyclic compounds useful as dual atx/ca inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2003082856A1 (fr) * 2002-03-22 2003-10-09 Eli Lilly And Company Derives d'acide isoquinoline-3-carboxylique en tant qu'antagonistes du recepteur d'acide amine excitateur
MX2007016180A (es) * 2005-06-14 2008-03-07 Schering Corp Inhibidores de aspartil proteasas.
RU2416603C9 (ru) 2005-10-25 2012-06-20 Сионоги Энд Ко., Лтд. Производные аминодигидротиазина
EP2151435A4 (fr) 2007-04-24 2011-09-14 Shionogi & Co Composition pharmaceutique pour le traitement de la maladie d'alzheimer
RU2476431C2 (ru) * 2008-01-18 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Конденсированное производное аминодигидротиазина
US8450331B2 (en) * 2008-04-22 2013-05-28 Merck Sharp & Dohme Corp. Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
WO2009151098A1 (fr) 2008-06-13 2009-12-17 塩野義製薬株式会社 DÉRIVÉ HÉTÉROCYCLIQUE CONTENANT DU SOUFRE AYANT UNE ACTIVITÉ INHIBANT LA β-SÉCRÉTASE
KR20110076965A (ko) 2008-09-30 2011-07-06 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 축합 아미노 디하이드로티아진 유도체
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
EP2511269A4 (fr) 2009-12-11 2013-04-24 Shionogi & Co Composé hétérocyclique fusionné comportant un groupement amino
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
EP2694521B1 (fr) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Composés de dioxyde de thiadiazine fusionnée à la pyrrolidine en tant qu'inhibiteurs de bace, compositions et leur utilisation
WO2012162334A1 (fr) 2011-05-24 2012-11-29 Bristol-Myers Squibb Company Composés destinés à la réduction de la production de bêta-amyloïdes
JO3143B1 (ar) * 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين

Also Published As

Publication number Publication date
PE20151542A1 (es) 2015-10-28
SG11201507499XA (en) 2015-10-29
JO3317B1 (ar) 2019-03-13
PH12015502031A1 (en) 2016-01-18
RS56645B1 (sr) 2018-03-30
ME02910B (fr) 2018-04-20
IL240903A0 (en) 2015-10-29
AR094918A1 (es) 2015-09-09
AU2014228351A1 (en) 2015-09-17
CN105026404B (zh) 2016-11-23
HRP20171851T1 (hr) 2018-01-12
HK1212694A1 (en) 2016-06-17
TN2015000340A1 (en) 2017-01-03
PL2970336T3 (pl) 2018-03-30
MY180083A (en) 2020-11-20
CA2898500A1 (fr) 2014-09-18
NO3039297T3 (fr) 2018-03-10
DK2970336T3 (da) 2017-11-13
US20140275044A1 (en) 2014-09-18
LT2970336T (lt) 2018-01-10
CN105026404A (zh) 2015-11-04
JP2016512252A (ja) 2016-04-25
PH12015502031B1 (en) 2016-01-18
CL2015002529A1 (es) 2016-03-28
CY1119585T1 (el) 2018-03-07
US8841293B1 (en) 2014-09-23
US20140350245A1 (en) 2014-11-27
BR112015018738A2 (pt) 2017-07-18
CR20150418A (es) 2015-09-16
TW201520217A (zh) 2015-06-01
NZ712207A (en) 2019-09-27
EP2970336B1 (fr) 2017-10-04
HUE037487T2 (hu) 2018-08-28
EA026006B1 (ru) 2017-02-28
MA38390B1 (fr) 2020-01-31
CA2898500C (fr) 2017-11-14
SI2970336T1 (sl) 2017-11-30
KR20150119070A (ko) 2015-10-23
UA112941C2 (uk) 2016-11-10
AP2015008713A0 (en) 2015-09-30
WO2014143579A1 (fr) 2014-09-18
IL240903B (en) 2018-12-31
BR112015018738A8 (pt) 2018-01-23
KR101688761B1 (ko) 2016-12-21
MX2015012628A (es) 2016-07-07
TWI593692B (zh) 2017-08-01
ES2653421T3 (es) 2018-02-07
PT2970336T (pt) 2017-12-21
EA201591491A1 (ru) 2016-01-29
EP2970336A1 (fr) 2016-01-20
US8987254B2 (en) 2015-03-24
JP6095844B2 (ja) 2017-03-15
US20150157641A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
MA38390B1 (fr) Composés tétrahydropyrrolothiazines
MA52948B1 (fr) Composés
MA38472B1 (fr) Composé peptidique
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
BR112017006253A2 (pt) novos compostos
EA201690172A1 (ru) Полиморф ингибиторов syk
MA38583B1 (fr) Dérivés de dolastatine 10 et d'auristatines
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
EA201792021A1 (ru) Ингибитор jak
MA40302B1 (fr) Dérivés de carbazole
EA201690911A1 (ru) Соединения диметилбензойной кислоты
MA37686A1 (fr) Composés phénoxyéthyl pipéridine
MA37501B1 (fr) Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
MX2015017156A (es) Inhibidores de bace.
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
MX2021012440A (es) Farmacos precursores de oxabicicloheptanos.
AR084172A1 (es) Derivados aminotriazol hidroxilados como agonistas del receptor alx
MA44781B1 (fr) Composé hétérocyclique condensé
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
MA39305A3 (fr) Dérivés d'éthynyle
EA201690924A1 (ru) Фторфенилпиразольные соединения
MA38857A1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
MA43231B1 (fr) Bloqueur des canaux sodiques